PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 18, 2024Minerva Urology and Nephrology7 citations

Major adverse cardiovascular events related to phosphodiesterase 5 inhibitors: analysis of real-life data from Eudra-Vigilance database

View Full Paper
CNCosimo De NunzioANAntonio NacchiaMGMaria Chiara Grimaldi

Key Points

Key points are not available for this paper at this time.

Abstract

Phosphodiesterase 5 inhibitors (PDE5i) are the standard medical treatment for erectile dysfunction. Aim of our study was to evaluate the rate of major adverse cardiovascular events (MACE) reported during PDE5i treatment based on Eudra-Vigilance (EV) reports.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Nunzio et al. (2024) studied this question.

synapsesocial.com/papers/68e7388db6db6435876b1ac8https://doi.org/10.23736/s2724-6051.23.05611-2
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Adverse events related to darolutamide treatment: analysis of "real life" data from EudraVigilance and the Food and Drug Administration database entries2023 · 4 citations
  2. 2Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension2005 · 2,483 citations
  3. 3Features of patients referring to the outpatient office due to benign prostatic hyperplasia: analysis of a national prospective cohort of 5815 cases2022 · 14 citations
  4. 4The Serendipitous Story of Sildenafil: An Unexpected Oral Therapy for Erectile Dysfunction2018 · 165 citations
  5. 5Have we mis-PRONOUNCEd the cardiovascular risk of GnRH agonists? A critical appraisal of the PRONOUNCE trial2022 · 4 citations